What is the antibiotic of choice for a patient diagnosed with brucellosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antibiotic of Choice for Brucellosis

The optimal first-line treatment for uncomplicated brucellosis is doxycycline 100 mg twice daily for 6 weeks combined with streptomycin 15 mg/kg daily intramuscularly for 2-3 weeks, as this regimen demonstrates the lowest relapse rates. 1, 2, 3

Primary Treatment Regimens

First-Line Option (Preferred)

  • Doxycycline-Streptomycin combination is the gold standard with superior efficacy compared to all other regimens 1, 2, 3
    • Doxycycline: 100 mg orally twice daily for 6 weeks 2, 3
    • Streptomycin: 15 mg/kg (approximately 1 g) intramuscularly daily for 2-3 weeks 2, 3
    • This combination has the lowest relapse rates (5-10%) among all treatment options 4

First-Line Alternative (When Streptomycin Unavailable)

  • Doxycycline-Gentamicin offers comparable efficacy with the advantage of wider availability 2, 4
    • Doxycycline: 100 mg orally twice daily for 6 weeks 2
    • Gentamicin: 5 mg/kg parenterally once daily for 7 days (not a fixed 500 mg dose) 2
    • Failure/relapse rates are approximately 10-20%, only 5% higher than streptomycin-containing regimens 2
    • The World Health Organization endorses this as a first-line option 2

Second-Line Option

  • Doxycycline-Rifampicin is acceptable but has higher relapse rates 1, 3, 4
    • Doxycycline: 100 mg orally twice daily for 6 weeks 2, 3
    • Rifampicin: 600-900 mg orally once daily (single morning dose) for 6 weeks 2, 3
    • Meta-analysis shows this regimen is inferior to doxycycline-streptomycin (OR = 3.17; 95% CI = 2.05-4.91) 4

Important Clinical Caveats

Public Health Consideration

  • In regions where tuberculosis and brucellosis coexist, avoid rifampicin-containing regimens when possible to prevent emergence of mycobacterial resistance to this critical anti-TB drug 1, 2, 5
  • The public health impact of rifampicin resistance may exceed the cumulative brucellosis morbidity 1

Treatment Duration

  • Six weeks is the standard duration for uncomplicated brucellosis 2, 3
  • Shorter durations (3 weeks) result in unacceptably high relapse rates 3
  • Even with optimal treatment, expect 5-15% relapse rates, though relapses are typically mild and respond to the same regimen 2, 3

Complicated Brucellosis Modifications

  • Brucellar spondylitis: Extend treatment to 12 weeks; aminoglycoside-containing regimens may be superior to rifampicin-containing ones 5, 3
  • Neurobrucellosis: Consider doxycycline plus rifampicin with an aminoglycoside (preferably gentamicin) 5
  • Brucellar endocarditis: Requires aggressive multi-drug therapy and often surgical intervention due to high mortality 3

Special Populations

  • Pregnant women: Rifampicin 900 mg once daily for 6 weeks is the drug of choice (tetracyclines are contraindicated) 6
  • Children <8 years: Use rifampicin plus trimethoprim-sulfamethoxazole for 45 days (avoid tetracyclines) 7, 6

Alternative Regimens (Cost-Effective Settings)

  • Trimethoprim-sulfamethoxazole (800+160 mg twice daily for 6 weeks) may be used in resource-limited settings with response rates above 90% 2
  • Quinolone-containing regimens (ofloxacin or ciprofloxacin) should be reserved as second or third agents in combination therapy 2, 8

Key Pitfall to Avoid

Never use monotherapy for brucellosis—all effective regimens require combination therapy to prevent relapse and treatment failure 1, 7, 9

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Brucellosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Brucellosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Neurobrucellosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Antibiotic treatment of brucellosis].

Presse medicale (Paris, France : 1983), 1994

Research

Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2004

Research

Update on brucellosis: therapeutic challenges.

International journal of antimicrobial agents, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.